Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its lead product candidate, YS-ON-001, for the treatment of hepatocellular carcinoma. YS-ON-001 is a promising biological product with
Read More